Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Pharmaceutical Technology

MAY 8, 2024

Zenas signed a licencing deal for Asia-Pacific territories for the bispecific antibody, obexelimab, with Bristol Myers Squibb in September.

Antibody 130

Antibody 130

Pharmaceutical Technology

MARCH 7, 2024

Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.

Antibody 162

Antibody 162

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

APRIL 4, 2024

Discover Xencor Inc's groundbreaking patent for novel GPC3 binding domains and bispecific antibodies targeting GPC3-associated cancers. Explore the innovative method for manufacturing these antibodies and their potential in cancer treatment.

Antibody 130

Antibody Manufacturing 130

Pharmaceutical Technology

MAY 28, 2024

J&J has made its second dermatology deal this month, adding Numab’s bispecific antibody NM26 to its growing atopic dermatitis drug portfolio.

Antibody 130

Antibody Dermatology Drugs 130

Drug Discovery World

JUNE 24, 2024

This eBook explores the challenges and opportunities in the therapeutic antibody market, the range of applications for these therapies and the move towards more targeted and effective next-generation antibody treatments.

Antibody 52

Antibody Drugs Marketing 52

Pharmaceutical Technology

JUNE 10, 2024

Discover Kodiak Sciences Inc's innovative method for treating wet age-related macular degeneration with an anti-VEGF antibody conjugate. Patented approach offers extended therapeutic effects for at least 12 weeks, providing a less frequent treatment option.

Antibody 130

Antibody 130

Bio Pharma Dive

MAY 28, 2024

The deal is J&J’s second this month involving bispecific antibodies, which the company has prioritized to build its immune and cancer drug pipeline.

Antibody 128

Antibody Drugs 128

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Drug Discovery World

JUNE 25, 2024

A new eBook, sponsored by Sino Biological, is now available for download entitled ‘ The impact of therapeutic antibody discovery ’. The first monoclonal antibody (mAb), Orthoclone, was approved in 1986 to help prevent rejection in organ transplantation.

Antibody 52

Antibody Clinical Research Drugs Research 52

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Licensing Licensing 264

Pharmaceutical Technology

APRIL 30, 2024

Discover a groundbreaking patent for treating CLEC12A positive cancer with bispecific antibodies. Learn about a unique dosing strategy to target cancer cells effectively while sparing hemopoietic stem cells.

Antibody 130

Antibody 130

BioSpace

MAY 23, 2024

Phase I/II data for Regeneron Pharmaceuticals’ costimulatory bispecific antibody were disappointing, with only one complete response when used as a combination treatment with Libtayo for solid tumors.

Antibody 127

Antibody 127

Pharmaceutical Technology

APRIL 18, 2024

Discover how Vir Biotechnology's patented multispecific antibodies target distinct Zika virus epitopes, neutralizing ZIKV infection. Explore the innovative potential for prophylaxis and treatment in this groundbreaking patent.

Antibody 130

Antibody 130

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Bio Pharma Dive

MAY 16, 2024

The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development.

Antibody 133

Antibody Drugs Development 133

Pharmaceutical Technology

APRIL 23, 2024

Discover how Yuhan Corp's patent for anti-PD-L1 IgG class antibodies revolutionizes manufacturing yields. Learn about the advancements in production efficiency and potential therapeutic applications.

Antibody 130

Antibody Manufacturing Production 130

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody 130

Antibody Development Engineer Drugs 130

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Pharmaceutical Technology

APRIL 10, 2024

Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 9, 2024

The grant will support the preclinical development of the antibody acquired by Basilea from Spexis in January.

Antibody 130

Antibody Development 130

BioPharma Reporter

JUNE 6, 2024

Alchemab Therapeutics, an antibody discovery company focused on identifying antibodies from individuals resilient to disease, has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinsonâs Research (MJFF) to propel its Parkinsonâs disease program forward.

Antibody 98

Antibody Research Development 98

Pharmaceutical Technology

FEBRUARY 22, 2024

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Antibody 130

Antibody Drugs 130

Pharmaceutical Technology

APRIL 22, 2024

Discover a broader repertoire of antibodies with a recently granted patent. Enhance immunoglobulin diversity with AbCellera's patented method for isolating B cells from genetically modified mice.

Genetics 130

Genetics Antibody Production 130

Pharmaceutical Technology

APRIL 23, 2024

UCB SA patent for IL-17A and IL-17F antibody molecules with expression vectors and host cell methods. Discover the innovative approach to efficient nucleic acid expression.

Antibody 130

Antibody 130

Pharmaceutical Technology

MARCH 28, 2024

Revolutionize cancer treatment with OSE Immunotherapeutics' patented anti-SIRPa antibodies targeting human SIRPa for enhanced T cell response and antigen presentation. Discover a comprehensive approach to treating various cancers with innovative combination therapies.

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 15, 2024

Discover Genzyme Corp's innovative method for detecting anti-drug antibodies in human body fluids. Learn how their patented process reduces interference in drug assays effectively.

Antibody 130

Antibody Drugs 130

Drug Discovery World

JUNE 20, 2024

Researchers have revealed that auto-antibodies block interferon signalling, contributing to severe Covid-19 by impairing the patient’s immune response. Scientists have found that some people who suffered from Covid-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signalling proteins.

Antibody 59

Antibody Immune Response Protein RNA 59

Pharmaceutical Technology

JUNE 19, 2024

Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.

Antibody 100

Antibody Clinical Development Development 100

Pharmaceutical Technology

APRIL 1, 2024

Treat systemic lupus erythematosus effectively with UCB SA's patented method using a specific antibody to CD154. Significant improvements in SLE indices and outcomes. Explore the potential of this innovative treatment now!

Antibody 130

Antibody 130

BioSpace

APRIL 12, 2024

This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.

Antibody 138

Antibody Drugs Research 138

Pharmaceutical Technology

FEBRUARY 22, 2024

Ono Pharmaceutical has partnered with EME to advance the drug discovery of VHH antibodies to develop new therapeutic agents.

Antibody 130

Antibody Drugs Development 130

Pharmaceutical Technology

APRIL 22, 2024

Discover the groundbreaking patent by OSE Immunotherapeutics SA for humanized monoclonal antibodies targeting CD127, offering innovative solutions for inhibiting inflammation and treating autoimmune, allergic, and viral diseases.

Antibody 130

Antibody 130

Pharmaceutical Technology

MAY 24, 2023

HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.

Antibody 147

Antibody Clinical Development Development Research 147

Pharmaceutical Technology

MARCH 26, 2024

Discover Pfizer's innovative patent for multi-drug Antibody Drug Conjugates and Linking Assembly Units, enabling precise and effective drug delivery. Explore the cutting-edge technology behind site-specific construction and versatile drug linking options.

Antibody 130

Antibody Drug Delivery Drugs 130

Pharmaceutical Technology

APRIL 23, 2024

Learn about modified antibodies and potential treatments in this groundbreaking publication. Discover Bristol-Myers Squibb's innovative patent for a pharmaceutical composition targeting human CD40 activity.

Antibody 130

Antibody 130